Printer Friendly

Articles from M2 Pharma (August 17, 2018)

1-25 out of 25 article(s)
Title Author Type Words
Agenus Receives Second Milestone Payment from Merck as Phase I Clinical Trial Launches. 242
Aquestive Therapeutics Underwriters Exercise Over-Allotment Option in US IPO. 259
Astellas promotes David Abbott as national vice president. 141
Avicanna closes acquisition of majority interest in Colombian Cannabis Cultivator. 315
Biohaven Reports Positive Results from Double-Blind, Placebo-Controlled, Investigator Initiated, Proof Of Concept Trial Of BHV-0223 For Anxiety. Financial report 745
BioNTech collaborates with Pfizer. 160
Calliditas Therapeutics widens loss in Q2 2018. Financial report 168
Cherry's profit up to SEK91m in Q2 2018. Financial report 126
Eisai Inc and Merck passes US FDA's approval for LENVIMA for the treatment of patients with unresectable hepatocellular carcinoma. 174
Ember Therapeutics to sell OP-1 portfolio to Viscogliosi Brothers. 136
Grifols Granted FDA Approval for New Consolidated Manufacturing Facility for Production of Recombinant Proteins. 514
HitGen enters innovative drug discovery research collaboration with LG Chem. 127
LakePharma Expands Antibody Centre into New San Carlos Building. 121
Novocure collaborates with US Oncology Research over pancreatic cancer study. 130
Ortho Dermatologics Resubmits US New Drug Application for DuobrII Lotion. 235
Regeneron, Teva Tout Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip. Clinical report 737
Shanghai ChemPartner closes merger agreement with Quantum. 168
Sirnaomics Oncology IND Receives Approval from US FDA to Initiate Study for Treatment of Cholangiocarcinoma. 684
Sirnaomics Oncology wins US FDA's approval to initiate study of STP705 in cholangiocarcinoma patients. 234
Synthorx names new chief medical officer. 207
Teva and Regeneron report positive Phase III fasinumab results. 171
The US FDA approves first generic EpiPen for the emergency treatment of allergic reactions. 237
Trovagene Completes Second Dosing Cohort of Patients Treated with Onvansertib in Ongoing Phase 1b/2 AML Trial. 859
USFDA grants approval to Sun Pharmaceutical Industries' CEQUA. 158
Zealand Pharma widens loss in H1 2018. 233

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters